Skip to main
CABA

Cabaletta Bio (CABA) Stock Forecast & Price Target

Cabaletta Bio (CABA) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Cabaletta Bio Inc. has garnered significant positive feedback from experts in cell and gene therapy, reinforcing its competitive positioning due to its unique preconditioning-free treatment approach, distinguishing itself from competitors. The company's promising early clinical results, exemplified by substantial patient improvements despite initial B cell depletion challenges, bolster the feasibility of expanding its innovative treatments across additional autoimmune indications. Furthermore, advancements in manufacturing efficiency have reduced costs, enhancing gross margins and strengthening the financial outlook as continued progress is anticipated to attract investor interest and drive stock performance.

Bears say

Cabaletta Bio Inc faces significant competitive risks in the cell therapy sector, which could hinder its market positioning amidst the rapid advancement of other therapies such as Rese-cel. The company's technology, while promising, shows that there is a heightened reluctance among potential patients to compromise on efficacy in treating serious conditions such as myositis and scleroderma, thus raising concerns about market acceptance. Additionally, the cost of goods sold (COGS) for its therapies, suggested to be around $50-100K per batch, may not sufficiently address the financial scalability needed to compete effectively in the current biotech landscape.

Cabaletta Bio (CABA) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cabaletta Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cabaletta Bio (CABA) Forecast

Analysts have given Cabaletta Bio (CABA) a Buy based on their latest research and market trends.

According to 7 analysts, Cabaletta Bio (CABA) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cabaletta Bio (CABA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.